SG Americas Securities LLC grew its holdings in Luminex Co. (NASDAQ:LMNX) by 17.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,226 shares of the medical instruments supplier’s stock after acquiring an additional 3,825 shares during the period. SG Americas Securities LLC’s holdings in Luminex were worth $853,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of LMNX. Mutual of America Capital Management LLC grew its position in Luminex by 22.9% in the first quarter. Mutual of America Capital Management LLC now owns 1,844 shares of the medical instruments supplier’s stock worth $51,000 after acquiring an additional 344 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of Luminex by 6,283.8% during the 1st quarter. Meeder Asset Management Inc. now owns 2,362 shares of the medical instruments supplier’s stock worth $64,000 after buying an additional 2,325 shares during the period. Banque Cantonale Vaudoise bought a new stake in shares of Luminex during the 1st quarter worth $70,000. PNC Financial Services Group Inc. boosted its holdings in shares of Luminex by 16.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,857 shares of the medical instruments supplier’s stock worth $78,000 after buying an additional 406 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Luminex by 30.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,163 shares of the medical instruments supplier’s stock worth $87,000 after buying an additional 747 shares during the period. 80.41% of the stock is owned by institutional investors.
Several analysts recently issued reports on LMNX shares. ValuEngine downgraded shares of Luminex from a “buy” rating to a “hold” rating in a report on Friday, May 1st. BidaskClub downgraded shares of Luminex from a “strong-buy” rating to a “buy” rating in a report on Friday.
Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, May 4th. The medical instruments supplier reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. Luminex had a negative net margin of 1.81% and a negative return on equity of 1.25%. The firm had revenue of $90.40 million during the quarter, compared to the consensus estimate of $82.30 million. During the same period in the prior year, the firm earned $0.07 EPS. The business’s revenue was up 9.7% on a year-over-year basis. Analysts expect that Luminex Co. will post 0.25 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, July 9th. Shareholders of record on Thursday, June 18th were issued a $0.09 dividend. This represents a $0.36 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date was Wednesday, June 17th. Luminex’s dividend payout ratio (DPR) is presently -171.43%.
In other news, SVP Nancy Fairchild sold 23,475 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $33.00, for a total value of $774,675.00. Following the completion of the transaction, the senior vice president now owns 60,899 shares in the company, valued at approximately $2,009,667. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director G Walter Loewenbaum II sold 86,657 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $31.27, for a total transaction of $2,709,764.39. The disclosure for this sale can be found here. Over the last three months, insiders sold 461,819 shares of company stock valued at $15,528,094. Insiders own 9.40% of the company’s stock.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.
Further Reading: What is the Euro STOXX 50 Index?
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.